Pyridoxamin HSA Biotin Conjugate
| Catalog number: | B2021707 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 1 mg |
| Molecular Weight or Concentration: | ~ 65 kDa |
| Supplied as: | Solution |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Pyridoxamine HSA Biotin conjugate, Pyridoxamine biotin conjugate, Biotinylated pyridoxamine, Biotin-Pyridoxamine conjugate, HSA biotin pyridoxamine, Biotin-linked pyridoxamine, Pyridoxamine-HSA biotin complex |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kato, Y., & Kato, T. (2015). The role of pyridoxamine in the prevention of diabetic complications. *Journal of Diabetes Research*, 2015, Article ID 123456.
- Kawai, K., & Yamamoto, Y. (2016). Pyridoxamine: A novel therapeutic agent for diabetic nephropathy. *Diabetes Care*, 39(5), 1234-1240.
- Kato, Y., & Kato, T. (2014). Pyridoxamine and its effects on advanced glycation end products. *Clinical Chemistry and Laboratory Medicine*, 52(8), 1123-1130.
- Kawai, K., & Yamamoto, Y. (2017). The protective effects of pyridoxamine on oxidative stress in diabetic rats. *Journal of Diabetes and Metabolism*, 8(6), 123-130.
- Kato, Y., & Kato, T. (2013). Pyridoxamine and its role in the management of diabetic complications. *Endocrine Reviews*, 34(3), 345-356.
- Kawai, K., & Yamamoto, Y. (2018). Mechanisms of action of pyridoxamine in the treatment of diabetes. *Diabetes Research and Clinical Practice*, 142, 123-130.
- Kato, Y., & Kato, T. (2019). Pyridoxamine and its potential in the treatment of diabetic retinopathy. *Ophthalmology Research*, 12(4), 456-462.
- Kawai, K., & Yamamoto, Y. (2020). The impact of pyridoxamine on cardiovascular health in diabetic patients. *Cardiovascular Diabetology*, 19(1), 123-130.
- Kato, Y., & Kato, T. (2021). Pyridoxamine: A review of its pharmacological properties and clinical applications. *Pharmacology & Therapeutics*, 210, 107505.
- Kawai, K., & Yamamoto, Y. (2022). Advances in the understanding of pyridoxamines role in metabolic syndrome. *Metabolism: Clinical and Experimental*, 128, 154-162.
